A detailed history of Ikarian Capital, LLC transactions in Allakos Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 972,675 shares of ALLK stock, worth $1.13 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
972,675
Previous 972,675 -0.0%
Holding current value
$1.13 Million
Previous $972,000 34.98%
% of portfolio
0.11%
Previous 0.39%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.0 - $1.45 $40,000 - $58,000
40,000 Added 4.29%
972,675 $972,000
Q1 2024

May 15, 2024

BUY
$1.02 - $3.23 $709,531 - $2.25 Million
695,619 Added 293.44%
932,675 $1.18 Million
Q4 2023

Feb 14, 2024

SELL
$1.72 - $3.18 $946,000 - $1.75 Million
-550,000 Reduced 69.88%
237,056 $647,000
Q3 2023

Nov 14, 2023

BUY
$2.13 - $5.55 $31,873 - $83,050
14,964 Added 1.94%
787,056 $1.79 Million
Q2 2023

Aug 14, 2023

BUY
$3.6 - $5.25 $2.78 Million - $4.05 Million
772,092 New
772,092 $3.37 Million
Q3 2021

Nov 15, 2021

SELL
$76.53 - $110.43 $13,316 - $19,214
-174 Reduced 0.55%
31,526 $3.34 Million
Q1 2021

May 17, 2021

BUY
$109.73 - $153.66 $3.48 Million - $4.87 Million
31,700 New
31,700 $3.64 Million
Q3 2020

Nov 16, 2020

SELL
$66.43 - $90.99 $2.83 Million - $3.87 Million
-42,536 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$44.04 - $80.69 $1.87 Million - $3.43 Million
42,536 New
42,536 $3.06 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $98.3M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.